ArticleInfection2022
Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.
Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Use of the test-negative design to estimate the protective effect of a scalar immune measure: a simulation analysis.American journal of epidemiology · 2026Article
- Article
- Article
- Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection.Antibodies (Basel, Switzerland) · 2024Article
- Article
- Reduced control of SARS-CoV-2 infection associates with lower mucosal antibody responses in pregnancy.mSphere · 2024Observational
- Article
- Neutralizing antibody and CD8Frontiers in immunology · 2024Article
- Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April-June 2022.Emerging infectious diseases · 2023Article
- Article
- Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration.Journal of medical virology · 2023Article
- Population-based study of the durability of humoral immunity after SARS-CoV-2 infection.Frontiers in immunology · 2023Article
- Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern.Frontiers in microbiology · 2023Article
- Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects.Infection · 2022Article
- Article
- Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers.Scientific reports · 2022Article
- IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study.Vaccine · 2022Observational
- Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel.Infection · 2022Article
- Article
- SARS Antibody Testing in Children: Development of Oral Fluid Assays for IgG Measurements.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-term course of immunity among individuals with a history of COVID-19, in particular among those who received a booster vaccination, has not been well defined so far.
methodsSARS-CoV-2-specific antibody levels were measured by ELISA over 1 year among 136 health care workers infected during the first COVID-19 wave and in a subgroup after booster vaccination approximately 1 year later. Furthermore, spike-protein-reactive memory T cells were quantified approximately 7 months after the infection and after booster vaccination. Thirty healthy individuals without history of COVID-19 who were routinely vaccinated served as controls.
resultsLevels of SARS-CoV-2-specific IgM- and IgA-antibodies showed a rapid decay over time, whereas IgG-antibody levels decreased more slowly. Among individuals with history of COVID-19, booster vaccination induced very high IgG- and to a lesser degree IgA-antibodies. Antibody levels were significantly higher after booster vaccination than after recovery from COVID-19. After vaccination with a two-dose schedule, healthy control subjects developed similar antibody levels as compared to individuals with history of COVID-19 and booster vaccination. SARS-CoV-2-specific memory T cell counts did not correlate with antibody levels. None of the study participants suffered from a reinfection.
conclusionsBooster vaccination induces high antibody levels in individuals with a history of COVID-19 that exceeds by far levels observed after recovery. SARS-CoV-2-specific antibody levels of similar magnitude were achieved in healthy, COVID-19-naïve individuals after routine two-dose vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.